“Confused and costly regulation” disadvantages New Zealand, submission on hazardous substances bill says
BioTech New Zealand has called for a “fundamental amendment” to how genetic technologies are regulated in the country.
In a submission on the Hazardous Substances and New Organisms (Hazardous Substances Assessments) Amendment Bill currently before New Zealand’s parliament, the industry body says that “genetic technologies face confused and costly regulation out of step with trading partners”. This is “to the marked disadvantage of New Zealand researchers and commercial businesses alike”, it says.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.